Beijing Biostar Pharmaceuticals Co Ltd

Chart & performance

D1W1MN

P/E

—

P/S

—

EPS

—

Vol. 1Y

—

Shs. 5Y

—

Rev. 5Y

Div Yld LY

—

Div Yld TTM

—

Revenues

37m

-52.36%

Net income

-143m

L-8.56%

CFO

-169m

L+40.74%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.

URL

https://www.biostar-pharm.com/

IPO date

Oct 31, 2024

Employees

Domiciled in

Incorporated in

Valuation

Latest on right Latest on left

Title in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT